‌

US Patent 11013741 AXL kinase inhibitors and use of the same

Patent 11013741 was granted and assigned to Sumitomo Dainippon Pharma Oncology on May, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

‌

Sumitomo Dainippon Pharma Oncology

Current Assignee

‌

Sumitomo Dainippon Pharma Oncology

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11013741

Date of Patent

May 25, 2021

Patent Application Number

16376452

Date Filed

April 5, 2019

Patent Citations

‌

US Patent 10125140 Crystalline forms of a bruton's tyrosine kinase inhibitor

‌

US Patent 10016435 Use of inhibitors of Bruton's tyrosine kinase (Btk)

‌

US Patent 10202356 JAK2 and ALK2 inhibitors and methods for their use

Patent Citations Received

‌

US Patent 11400091 AXL kinase inhibitors and use of the same

Patent Primary Examiner

‌

Golam M. Shameem

Patent abstract

Tartrate salts of the compound of structure (I),

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11013741 AXL kinase inhibitors and use of the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API